Heska Corporation Fourth Quarter and Full Year 2019 Financial Results and Earnings Call Scheduled for February 25, 2020

LOVELAND, Colorado, Feb. 4, 2020 /PRNewswire/ -- Heska Corporation , a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and full year 2019 financial performance in a press release on Tuesday, February 25, 2020 before the market opens, and to host an earnings call to discuss the results following the release at 9 a.m. MT / 11 a.m. ET.

https://mma.prnewswire.com/media/832042/heska_Logo.jpg [https://mma.prnewswire.com/media/832042/heska_Logo.jpg]

To access the conference call: From within the United States, please dial 1-888-259-8389 From outside of the United States, please dial 1-323-794-2570 Reference Conference ID: 6976509

The earnings call will be webcast live from the Company's website at https://ir.heska.com/ [https://c212.net/c/link/?t=0&l=en&o=2710159-1&h=554007805&u=https%3A%2F%2Fir.heska.com%2F&a=https%3A%2F%2Fir.heska.com%2F].

A telephonic replay will be available beginning at 2 p.m. ET February 25 and will continue through 11:59 p.m. ET on Tuesday, March 10, 2020. The webcast will be archived on www.heska.com for 90 days.

To access the replay: From within the United States, please dial 1-844-512-2921 From outside the United States, please dial 1-412-317-6671 Reference Replay Pin Number: 6976509

About Heska Heska Corporation manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through two business segments. The Core Companion Animal Health ("CCA") segment represents approximately 85% of revenues, and the Other Vaccines and Pharmaceuticals ("OVP") segment represents approximately 15% of revenues, as of September 30, 2019. CCA segment includes Point of Care Laboratory testing instruments and consumables, primarily under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes private label vaccine and pharmaceutical production under third party agreements and channels, primarily for herd animal health.

Logo - https://mma.prnewswire.com/media/832042/heska_Logo.jpg [https://c212.net/c/link/?t=0&l=en&o=2710159-1&h=2274278316&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F832042%2Fheska_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F832042%2Fheska_Logo.jpg]

CONTACT: Heska Corporation, Jon Aagaard, Director, Investor Relations, 970.619.3033, investorrelations@heska.com

Web site: https://ir.heska.com/

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234